Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/353568
Type: Outro documento
Title: Erratum to “Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia”
Author: Rodrigues, C.A.
Gonçalves, M.V.
Ikoma, M.R.V.
Lorand-Metze, I.
Pereira, A.D.
Farias, D.L.C.D.
Chauffaille, M.D.L.L.F.
Schaffel, R.
Ribeiro, E.F.O.
Rocha, T.S.D.
Buccheri, V.
Vasconcelos, Y.
Figueiredo, V.L.D.P.
Chiattone, C.S.
Yamamoto, M.
Brazilian Group of Chronic Lymphocytic Leukemia
Abstract: In the article “Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia”, published in Rev Bras Hematol Hemoter 2016;38:346–57, please consider the following correction: 2) Relapsed first-line treatment: a) Progress after 24 months: repeat first-line treatment (add an anti-CD20 antibody if not used in the first-line treatment)b) Progress within 24 months: - ‘Go-go’ patients: ibrutinib • Alternative options: venetoclax, alemtuzumab with or without methylprednisolone, rituximab with or without high-dose methylprednisolone, allogeneic HCST, bendamustine plus rituximab- ‘Slow-go’ patients: ibrutinib • Alternative options: idelalisib plus rituximab, alemtuzumab with or without methylprednisolone, rituximab with or without high-dose methylprednisolone bendamustine plus rituximab, FCR-lite © 2016 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular
Subject: Leucemia
Country: Brasil
Editor: Associação Brasileira de Hematologia e Hemoterapia
Rights: Aberto
Identifier DOI: 10.1016/j.bjhh.2017.01.002
Address: https://www.sciencedirect.com/science/article/pii/S1516848417300075
Date Issue: 2017
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.